A1 Refereed original research article in a scientific journal
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
Authors: Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Gago FJF, Hakkarainen A, Sipila P, Haggblad M, Martens U, Lundgren B, Frigault MM, Lane DP, Swartling FJ, Uhrbom L, Nestor M, Marino S, Nelander S
Publisher: CELL PRESS
Publication year: 2020
Journal: Cell Reports
Journal name in source: CELL REPORTS
Journal acronym: CELL REP
Article number: ARTN 107897
Volume: 32
Issue: 2
Number of pages: 25
ISSN: 2211-1247
DOI: https://doi.org/10.1016/j.celrep.2020.107897
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/48996948
Glioblastoma (GBM) is a malignant brain tumor with few therapeutic options. The disease presents with a complex spectrum of genomic aberrations, but the pharmacological consequences of these aberrations are partly unknown. Here, we report an integrated pharmacogenomic analysis of 100 patient-derived GBM cell cultures from the human glioma cell culture (HGCC) cohort. Exploring 1,544 drugs, we find that GBM has two main pharmacological subgroups, marked by differential response to proteasome inhibitors and mutually exclusive aberrations in TP53 and CDKN2A/B. We confirm this trend in cell and in xenotransplantation models, and identify both Bcl-2 family inhibitors and p53 activators as potentiators of proteasome inhibitors in GBM cells, We can further predict the responses of individual cell cultures to several existing drug classes, presenting opportunities for drug repurposing and design of stratified trials. Our functionally profiled biobank provides a valuable resource for the discovery of new treatments for GBM.
Downloadable publication This is an electronic reprint of the original article. |  |
